AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05754073
Drug: 1. Intranasal oxytocin spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
Trial: NCT05754073
Drug: 3. Intranasal Oxytocin spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
Trial: NCT05819684
Drug: SHR-4602 for injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: be administered via intravenous (IV) infusion
Trial: NCT05776797
Drug: Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimal medication therapy according to the prescription of the physician.
Trial: NCT05700448
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT05700448
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT05700448
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT05478499
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05931484
Drug: Gemfibrozil
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT04127968
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children in intervention group will receive 50,000 IU vitamin A after being randomized.
Trial: NCT04127968
Drug: Oil
RxNorm normalized name: Oil
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children in control group will receive equal volume of oil.
Trial: NCT05235737
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adding Pembrolizumab as a neoadjuvant and adjuvant therapy to the standard of care protocol
Trial: NCT05235737
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adding Pembrolizumab as a neoadjuvant therapy to the standard of care protocol
Trial: NCT05910827
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
Trial: NCT05910827
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
Trial: NCT06798727
Drug: High Hyal Plus
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
Trial: NCT06045936
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 teaspoons of 2% lidocaine injection
Trial: NCT04806451
Drug: Crinecerfont
RxNorm normalized name: Crinecerfont
DrugBank: Crinecerfont (DB18518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRF type 1 receptor antagonist
Trial: NCT05097378
Drug: Encorafenib + Binimetinib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor, which suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated forms of BRAF kinase (V600E, D and K).~Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Binimetinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity
Trial: NCT05563480
Drug: TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Trial: NCT05563480
Drug: Penpulimab injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Trial: NCT05563480
Drug: TQB2618 injection; Penpulimab injection
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2618 injection: Anti-TIM-3 monoclonal antibody; Penpulimab injection: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Trial: NCT04605549
Drug: CIN-107 2 mg dosing
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
Trial: NCT04605549
Drug: CIN-107 4 mg dosing
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
Trial: NCT04605549
Drug: CIN-107 8 mg dosing
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
Trial: NCT05076175
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04908956
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home.
Trial: NCT05273398
Drug: nasal diazepam
RxNorm normalized name: diazepam Nasal Spray
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal administration of diazepam
Trial: NCT04822961
Drug: Senaparib
RxNorm normalized name: Senaparib
DrugBank: Senaparib (DB17163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg capsules
Trial: NCT05445778
Drug: Mirvetuximab soravtansine plus Bevacizumab
RxNorm normalized name: mirvetuximab soravtansine
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
Trial: NCT05445778
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Bevacizumab 15mg/kg every 3 weeks
Trial: NCT05894577
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
Trial: NCT06797622
Drug: Trastuzumab deruxtecan (T-DXd)
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd)
Trial: NCT05303090
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Trial: NCT05303090
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Trial: NCT06546384
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with semaglutide, following standard clinical practice as per below schedule:~Week 1-4: Injected dose of 0,25 mg i.d. Week 5-8: Injected dose of 0,5 mg i.d. Week 9-12: Injected dose of 1,0 mg i.d. Week 13-16: Injected dose of 1,7 mg i.d. After week 16: Injected dose of 2,4 mg i.d.
Trial: NCT06801730
Drug: Irinotecan liposome combined with bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Irinotecan liposomes, 50mg/m2, d1, 90 min intravenously, Q2W; Bevacizumab 10mg/kg, d1, Q2W;
Trial: NCT06346691
Drug: Doxofylline
RxNorm normalized name: Doxofylline
DrugBank: Doxofylline (DB09273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
Trial: NCT06346691
Drug: Procaterol
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
Trial: NCT06800612
Drug: Oncologic drugs administered for treatment of breast cancer
RxNorm normalized name: chicken breast preparation
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data on oncologic drugs administered for treatment of breast cancer will be recorded
Trial: NCT05113342
Drug: Descartes-25
RxNorm normalized name: Descartes 30
DrugBank: Descartes-30 (DB16361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allogeneic Mesenchymal Stem Cell product.
Trial: NCT06801249
Drug: Metarapone
RxNorm normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and 11-deoxycorticosterone (DOC) to corticosterone.
Trial: NCT06800378
Drug: Zolpidem 10 mg
RxNorm normalized name: zolpidem 10 mg oral tablet
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem tartrate 10 mg tablet (taken before bedtime)
Trial: NCT05983159
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alpha-specific PI3-kinase inhibitor
Trial: NCT05983159
Drug: Mirdametinib
RxNorm normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An investigational oral MEK inhibitor
Trial: NCT06801353
Drug: Mometasone Furoate Nasal Spray (MFNS)
RxNorm normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mometasone furoate nasal spray 200 μg once daily
Trial: NCT06377852
Drug: Palbociclib 125mg
RxNorm normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)
Trial: NCT06377852
Drug: Ribociclib 600mg
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)
Trial: NCT06377852
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
Trial: NCT06377852
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
Trial: NCT05620771
Drug: Atezolizumab and Bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
Trial: NCT04782960
Drug: Iocal anaesthetic bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anaesthetic Subconjunctival bupivacaine
Trial: NCT06013345
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: analgosedation without secured airway
Trial: NCT06013345
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: analgosedation with secured airway
Trial: NCT06013345
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIVA with secured airway
Trial: NCT05491278
Drug: Fospropofol disodium for injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
Trial: NCT05610085
Drug: Levetiracetam Injection
RxNorm normalized name: levetiracetam Injection
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
Trial: NCT05610085
Drug: Phenobarbital Sodium Injection
RxNorm normalized name: Phenobarbital Sodium Injection
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for neonatal seizures
Trial: NCT05491278
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
Trial: NCT06162221
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion
Trial: NCT06162221
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT06162221
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Infusion
Trial: NCT06162221
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT06801470
Drug: CD-001
RxNorm normalized name: CD
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD-001 administered as an intravenous (IV) infusion.
Trial: NCT05918328
Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: albumin paclitaxel （260mg/㎡ every 3 weeks or 125mg/㎡ weekly）+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg, once every 3 weeks)+pyrrolitinib (320mg, QD), 3 weeks as one cycle.
Trial: NCT05918328
Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab
RxNorm normalized name: Carboplatin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
Trial: NCT04652726
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
Trial: NCT04541147
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.
Trial: NCT04613453
Drug: Ketamine Infusion
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
Trial: NCT04613453
Drug: Midazolam Infusion
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
Trial: NCT06286397
Drug: 1% Clascoterone
DrugBank: Clascoterone (DB12499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
Trial: NCT06204094
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg intravenous infusion d1 of each cycle\*8cycles
Trial: NCT06204094
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m2, intravenous infusion,d1 of each cycle\*8cycles
Trial: NCT04535271
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Trial: NCT04711863
Drug: Fluvoxamine
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
Trial: NCT04785833
Drug: T cell injection targeting CD7 chimeric antigen receptor
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
Trial: NCT05263947
Drug: Bevacizumab and Icotinib
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
Trial: NCT05618028
Drug: ABBV-525
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT06041776
Drug: Befotertinib + Icotinib placebo
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of Befotertinib is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis)~Icotinib placebo 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).
Trial: NCT06041776
Drug: Icotinib + Befotertinib placebo
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib 125 mg three times daily, on an empty stomach or in combination with food, use medication until the disease relapses or intolerable toxicity occurs or treatment lasts for 2 years (disease recurrence includes local recurrence and/or distant metastasis).~The initial dose of Befotertinib placebo is 75 mg orally once daily (QD) for 21 days, and then increased to 100 mg orally QD in the absence of serious side effects , CTCAE grade ≥ 2 headache or thrombocytopenia during the 21 days.~Befotertinib placebo can be taken on an empty stomach or after meals, and the medication is used until the disease relapses or intolerable toxicity occurs, or the treatment lasts for 3 years (disease recurrence includes local recurrence and/or distant metastasis.
Trial: NCT04724447
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x 450mg VGCV tablets
Trial: NCT00000843
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no